Zevra Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Zevra Therapeutics, Inc. (ZVRA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $11.74 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-08-10
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $6.04M.
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $5.70M.
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was $5.74M.
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was $2.52M.
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$46.95M.
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$19.14M.
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$47.00K.
- Zevra Therapeutics, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$34.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2017-06-30 | $6.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $11.74M 10-Q · filed 2017-08-10 | $17.48M derived: sum of 3 quarters · filed 2017-08-10 | $20.00M derived: sum of 4 quarters · filed 2017-08-10 | |
| 2017-03-31 | $5.70M 10-Q · filed 2017-05-22 | $11.44M derived: sum of 2 quarters · filed 2017-05-22 | $13.96M derived: sum of 3 quarters · filed 2017-05-22 | -$26.51M derived: sum of 4 quarters · filed 2017-08-10 | |
| 2016-12-31 | $5.74M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $8.25M derived: sum of 2 quarters · filed 2017-03-10 | -$32.22M derived: sum of 3 quarters · filed 2017-08-10 | -$46.95M 10-K · filed 2017-03-10 | |
| 2016-09-30 | $2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$37.95M derived: sum of 2 quarters · filed 2017-08-10 | -$52.69M 10-Q · filed 2016-11-10 | -$71.73M derived: sum of 4 quarters · filed 2017-08-10 | |
| 2016-06-30 | -$40.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$55.20M 10-Q · filed 2017-08-10 | -$56.30M 10-Q · filed 2016-08-11 | -$74.24M derived: sum of 3 quarters · filed 2017-08-10 | -$74.30M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | -$14.73M 10-Q · filed 2017-05-22 | -$33.77M derived: sum of 2 quarters · filed 2017-05-22 | -$33.83M derived: sum of 3 quarters · filed 2017-05-22 | -$33.85M derived: sum of 4 quarters · filed 2017-05-22 | |
| 2015-12-31 | -$19.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$19.10M derived: sum of 2 quarters · filed 2017-03-10 | -$19.12M derived: sum of 3 quarters · filed 2017-03-10 | -$19.14M 10-K · filed 2017-03-10 | |
| 2015-09-30 | -$55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$74.00K derived: sum of 2 quarters · filed 2016-11-10 | -$95.00K 10-Q · filed 2016-11-10 | -$125.00K derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$40.00K 10-Q · filed 2016-08-11 | -$70.00K derived: sum of 3 quarters · filed 2017-03-10 | -$76.00K derived: sum of 4 quarters · filed 2017-03-10 | |
| 2015-03-31 | -$21.00K 10-Q · filed 2016-05-13 | -$51.00K derived: sum of 2 quarters · filed 2017-03-10 | -$57.00K derived: sum of 3 quarters · filed 2017-03-10 | -$64.00K derived: sum of 4 quarters · filed 2017-03-10 | |
| 2014-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$36.00K derived: sum of 2 quarters · filed 2017-03-10 | -$43.00K derived: sum of 3 quarters · filed 2017-03-10 | -$47.00K 10-K · filed 2017-03-10 | |
| 2014-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | -$13.00K derived: sum of 2 quarters · filed 2015-11-13 | -$17.00K 10-Q · filed 2015-11-13 | ||
| 2014-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | -$11.00K 10-Q · filed 2015-08-14 | |||
| 2014-03-31 | -$4.00K 10-Q · filed 2015-05-29 | ||||
| 2013-12-31 | -$34.00K 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |